A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Related tests | Test | Basic Links | |||||||||||||||||||||||
2 | Vascular and viral regulation | ROCK1 (rho-associated, coiled-coil-containing protein kinase 1) | ||||||||||||||||||||||||
3 | Plays a role in viral infections. Involved in cell shape, migration, and proliferation | https://academic.oup.com/ehjcvp/article/9/4/371/7109259 | ||||||||||||||||||||||||
4 | ROCK2 (rho-associated, coiled-coil-containing protein kinase 2) | |||||||||||||||||||||||||
5 | Similar to ROCK1 in function | https://academic.oup.com/ehjcvp/article/9/4/371/7109259 | ||||||||||||||||||||||||
6 | RAAS system | Ang-(1-7) (Angiotensin 1-7) | ||||||||||||||||||||||||
7 | Vasodilator peptide of the renin-angiotensin system, mainly generated by ACE2. Affects cardiovascular organs with functions opposed by Ang II. May be low in LC. | https://www.heartrhythmjournal.com/article/S1547-5271(10)01204-X/abstract | ||||||||||||||||||||||||
8 | ACE2 (angiotensin-converting enzyme 2) | |||||||||||||||||||||||||
9 | Angiotensin-converting enzyme 2, converts Ang II to Ang-(1-7) | https://www.heartrhythmjournal.com/article/S1547-5271(10)01204-X/abstract | https://www.mdpi.com/1422-0067/24/18/13957 | |||||||||||||||||||||||
10 | ANG II (Angiotensin II) | |||||||||||||||||||||||||
11 | Part of the RAAS cycle, a hormone that causes vasoconstriction and increases blood pressure. ANG II promotes ROS production. High levels seen in POTS with low blood volume and flow | https://www.heartrhythmjournal.com/article/S1547-5271(10)01204-X/abstract | https://www.mdpi.com/1422-0067/24/18/13957 | |||||||||||||||||||||||
12 | ANG I (Angiotensin I) | |||||||||||||||||||||||||
13 | Precursor to Ang II, formed from angiotensinogen | |||||||||||||||||||||||||
14 | ACE (angiotensin converting enzyme) | |||||||||||||||||||||||||
15 | Converts Ang I to Ang II | |||||||||||||||||||||||||
16 | Tgfb system | TGFβ1 (Transforming growth factor beta 1) | ||||||||||||||||||||||||
17 | High levels in LC/ME may indicate disease severity. Regulates immune system and is highly immunosuppressive | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04149-9 | ||||||||||||||||||||||||
18 | TGFβ2 (Transforming growth factor beta 2) | Read doc link for all tgfb info | ||||||||||||||||||||||||
19 | Similar function to TGFβ1 | https://docs.google.com/document/d/12IFYiMyQyuSr6WgxElGqrRqJS_fbbm-DfBKNfkXLLWQ/edit | ||||||||||||||||||||||||
20 | TGFβ3 (Transforming growth factor beta 3) | |||||||||||||||||||||||||
21 | Similar function to TGFβ2 | |||||||||||||||||||||||||
22 | Activin B | |||||||||||||||||||||||||
23 | Elevated levels in ME patients may be linked to muscle loss and altered NK cell function | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1161-4 | ||||||||||||||||||||||||
24 | Follistatin (activin-bindings protein) | |||||||||||||||||||||||||
25 | An antagonist of myostatin that can increase muscle mass and strength. Found to be reduced in the blood of ME/CFS patients compared to reference values. When added to blood of ME/CFS patients in another study, it reversed PD-1 activation | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1161-4 | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1161-4 | |||||||||||||||||||||||
26 | Hypoxia | Hif-1α (Hypoxia-inducible factor 1-alpha) | ||||||||||||||||||||||||
27 | Expected to be elevated. May indicate vasculo-proliferative disease with impact on the brain and heart. When oxygen levels drop, HIF-1α levels rise, triggering many downstream processes. Interlinked with TGFβ, Ang-(1-7)/ANG II | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04149-9 | ||||||||||||||||||||||||
28 | Mitochondria | DRP1 (Mitochondrial dynamin-related protein 1) | ||||||||||||||||||||||||
29 | Regulates mitochondrial fission. Increased DRP1 increases mitochondrial fission and is involved in coordinating the response to viral infections and signalling to the immune system | https://www.nature.com/articles/s41586-022-04667-4 | ||||||||||||||||||||||||
30 | PINK-1 (PTEN-induced kinase 1:) | |||||||||||||||||||||||||
31 | Regulates mitochondrial quality control and autophagy. Elevated levels may indicate mitochondrial damage | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.681386/full | ||||||||||||||||||||||||
32 | SIRT1 (NAD-dependent deacetylase sirtuin-1) | |||||||||||||||||||||||||
33 | The SIRT1 protein is located in all cells. Its job in the nucleus of the cell is to remove the acetyl groups from histones, which regulates gene expression. It's a regulator reacting to the energy available in the cell. Upregulation encourages the switch from ATP generation via aerobic glycolysis to fatty acid oxidation. | https://www.meresearch.org.uk/research/sirt1-nos-axis/ | ||||||||||||||||||||||||
34 | PGE2 (Prostaglandin E2) | |||||||||||||||||||||||||
35 | PGEs are synthesized by mast cells. High levels may be related to mast cell activation syndrome (MCAS) | https://academic.oup.com/cid/article/73/12/2228/6141511?login=false | ||||||||||||||||||||||||
36 | Immune system | IFNα (Interferon alpha) | ||||||||||||||||||||||||
37 | High levels of IFNa are associated with Lyme disease and may predict the likelihood of it becoming chronic. IFNa initiates the itaconate pathway. | https://wwwnc.cdc.gov/eid/article/29/6/22-1685-f3 | ||||||||||||||||||||||||
38 | IFNβ (Interferon beta) | |||||||||||||||||||||||||
39 | Interferon beta is a cytokine involved in the regulation of immune responses | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1254899 | https://www.nature.com/articles/s41590-021-01113-x | |||||||||||||||||||||||
40 | IFNγ (Interferon gamma) | |||||||||||||||||||||||||
41 | A cytokine that plays an important role in inducing and modulating an array of immune responses. High levels have been observed in long COVID compared to recovered COVID patients. | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283983 | ||||||||||||||||||||||||
42 | IFNL1 (Interferon lambda 1) | |||||||||||||||||||||||||
43 | Expected to be high in LC | https://www.nature.com/articles/s41590-021-01113-x | ||||||||||||||||||||||||
44 | Nagalase (α-N-acetylgalactosaminidase) | |||||||||||||||||||||||||
45 | Enzyme secreted during Warburg metabolism | https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2070667 | ||||||||||||||||||||||||
46 | Autophagy | ATG13 (Autophagy Related protein 13) | ||||||||||||||||||||||||
47 | Biomarker used in studies involving Rapamycin, a drug that induces autophagy | https://www.sciencedirect.com/science/article/abs/pii/S1044743122000379 | ||||||||||||||||||||||||
48 | Blood brain barrier | NEFL (Neurofilament Light Chain) | ||||||||||||||||||||||||
49 | A brain inflammation marker (NfL) that is a non-specific biomarker for several neurodegenerative conditions, including Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). | https://academic.oup.com/painmedicine/article/23/4/774/6472363 | ||||||||||||||||||||||||
50 | S100B (S100 calcium-binding protein B) | |||||||||||||||||||||||||
51 | A protein that is elevated after head trauma or blood-brain barrier dysfunction | https://www.nature.com/articles/s41598-020-75618-0 | ||||||||||||||||||||||||
52 | Neuro chemical | Serotonin | ||||||||||||||||||||||||
53 | Neurotransmitter that may be low in LC | https://www.sciencedirect.com/science/article/pii/S0092867423010346 | ||||||||||||||||||||||||
54 | Vascular (and immune) | ARG1 (Arginase1) | ||||||||||||||||||||||||
55 | Upregulated during SARS-CoV-2 infection, diminishing arginine levels. Studies show it is reduced in Multiple Sclerosis patients. | https://academic.oup.com/cid/article/73/12/2228/6141511?login=false | ||||||||||||||||||||||||
56 | BH2 (Dihydrobiopterin) | |||||||||||||||||||||||||
57 | ME patients may have high BH2 and low BH4 (higher BH2/BH4 ratio) | https://assets.researchsquare.com/files/rs-3716093/v1_covered_33e44b9d-4374-4e01-addf-51629ae8c203.pdf?c=1709739857 | ||||||||||||||||||||||||
58 | BH4 (Tetrahydrobiopterin) | |||||||||||||||||||||||||
59 | An essential cofactor needed for the production of neurotransmitters and nitric oxide | https://assets.researchsquare.com/files/rs-3716093/v1_covered_33e44b9d-4374-4e01-addf-51629ae8c203.pdf?c=1709739857 | ||||||||||||||||||||||||
60 | Exercise intolerance | TWEAK (TNF-related weak inducer of apoptosis) | ||||||||||||||||||||||||
61 | A novel cytokine that causes exercise intolerance when elevated | https://skeletalmusclejournal.biomedcentral.com/articles/10.1186/2044-5040-3-18 | ||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||
63 | Please note that the references provided are only basic, relevant links. Much more information is available on each marker and how it may apply in specific disease contexts. If you're interested in learning more about any of these markers, please conduct further research on your own. | |||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||
100 |